Long-term safety study of brivaracetam in childhood or juvenile absence epilepsy

Phase 3, open-label, single-arm trial of brivaracetam in childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE), sponsored by UCB. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of treatment-emergent adverse events leading to discontinuation. Started Nov 2024; status: completed.